Non-survivors (N=15) | Survivors (N=223) | p Value | |
---|---|---|---|
Age (years) | 70±9 | 69±12 | 0.933 |
Male, n (%) | 6 (40.0) | 96 (43.0) | 0.999 |
Body weight (kg) | 64.7±13.5 | 67.4±14.1 | 0.576 |
Systolic BP (mm Hg) | 134±22 | 140±19 | 0.300 |
Diastolic BP (mm Hg) | 73±9 | 77±12 | 0.193 |
Fasting glucose (mmol/L) | 12.7±11.1 | 9.9±7.2 | 0.160 |
eGFR (mL/min/1.73 m2) | 56±22 | 59±28 | 0.749 |
Total cholesterol (mmol/L) | 4.4±1.0 | 4.3±0.9 | 0.674 |
HDL cholesterol (mmol/L) | 1.2±0.3 | 1.3±0.4 | 0.421 |
Triglyceride (mmol/L) | 1.9±0.9 | 1.6±1.2 | 0.369 |
ABI | 1.1±0.1 | 1.1±0.1 | 0.688 |
baPWV (cm/s) | 2171±460 | 1909±427 | 0.023 |
%MAP | 42.2%±4.9 | 40.0%±4.1 | 0.044 |
UT (ms) | 166±41 | 155±29 | 0.167 |
Diabetes mellitus, n (%) | 12 (80.0) | 173 (77.6) | 0.999 |
CAD, n (%) | 2 (13.3) | 37 (16.6) | 0.999 |
Antiplatelet, n (%) | 2 (13.3) | 52 (23.3) | 0.565 |
Antihypertensive agents | |||
ACE inhibitor or ARB, n (%) | 8 (53.3) | 103 (46.2) | 0.787 |
α-Blocker, n (%) | 4 (26.7) | 18 (8.1) | 0.052 |
β-Blocker, n (%) | 2 (13.3) | 29 (13.0) | 0.999 |
Calcium channel blocker, n (%) | 2 (13.3) | 67 (30.0) | 0.277 |
Diuretics, n (%) | 4 (26.7) | 33 (14.8) | 0.390 |
Antidiabetic drugs | |||
Insulin therapy, n (%) | 4 (26.7) | 59 (26.5) | 0.999 |
Insulin secretagogues, n (%) | 3 (20.0) | 75 (33.6) | 0.421 |
Metformin, n (%) | 3 (20.0) | 78 (35.0) | 0.366 |
Thiazolidinediones, n (%) | 0 (0.0) | 16 (7.2) | 0.588 |
α-Glucosidase inhibitor, n (%) | 0 (0.0) | 9 (4.0) | 0.925 |
%MAP, percentage of mean arterial pressure; ABI, ankle-brachial index; ARB, angiotensin II receptor antagonists; baPWV, brachial-ankle pulse wave velocity; BP, blood pressure; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; UT, upstroke time.